FEV₃/FEV₆在医疗服务不足地区对慢性阻塞性肺疾病的早期诊断及预后价值
Early diagnostic and prognostic value of FEV₃/FEV₆ for COPD in underserved areas.
作者信息
Li Fei, Han Yancong, Yao Xiaoling, Zhao Fang, Zhao Qing, Liu Weilin
机构信息
Health Care Department, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Health Care Department, The Eighth People's Hospital of Hebei, Shijiazhuang, China.
出版信息
Front Med (Lausanne). 2025 Aug 8;12:1627615. doi: 10.3389/fmed.2025.1627615. eCollection 2025.
BACKGROUND
Chronic obstructive pulmonary disease (COPD) presents a major global health burden. While FEV1/FVC is the diagnostic gold standard, its application is limited by patient compliance and procedural complexity. FEV3/FEV6 has been proposed as a simpler alternative for early COPD screening, but its diagnostic and prognostic value remains unclear. This study aims to evaluate the effectiveness of FEV3/FEV6 in diagnosing mild to moderate COPD and predicting patient outcomes.
METHODS
A total of 200 patients suspected of having mild to moderate COPD underwent FEV3/FEV6 and FEV1/FVC testing from June 2019 to June 2021 and were followed for 3 years. Correlation analysis and ROC curve analysis were conducted.
RESULTS
FEV6 correlated strongly with FVC ( = 0.981) and FEV3/FEV6 with FEV1/FVC ( = 0.928). FEV3/FEV6 showed high diagnostic accuracy (AUC = 0.953; sensitivity 87.92%; specificity 84.77%) and prognostic relevance (AUC = 0.783; sensitivity 80.3%; specificity 66.2%).
CONCLUSION
FEV3/FEV6 is a reliable tool for early diagnosis and prognosis assessment in mild to moderate COPD.
背景
慢性阻塞性肺疾病（COPD）是一项重大的全球健康负担。虽然FEV1/FVC是诊断的金标准，但其应用受到患者依从性和操作复杂性的限制。FEV3/FEV6已被提议作为早期COPD筛查的一种更简单的替代方法，但其诊断和预后价值仍不明确。本研究旨在评估FEV3/FEV6在诊断轻度至中度COPD及预测患者预后方面的有效性。
方法
2019年6月至2021年6月，共有200例疑似患有轻度至中度COPD的患者接受了FEV3/FEV6和FEV1/FVC检测，并进行了3年的随访。进行了相关性分析和ROC曲线分析。
结果
FEV6与FVC高度相关（r = 0.981），FEV3/FEV6与FEV1/FVC高度相关（r = 0.928）。FEV3/FEV6显示出较高的诊断准确性（AUC = 0.953；灵敏度87.92%；特异度84.77%）和预后相关性（AUC = 0.783；灵敏度80.3%；特异度66.2%）。
结论
FEV3/FEV6是轻度至中度COPD早期诊断和预后评估的可靠工具。
Zotero 插件